Last reviewed · How we verify

NCT06123689

Safety and Efficacy of AMT-RegeneraActiva in the Management of Knee Osteoarthritis (OA)

Withdrawn NA Last updated 3 July 2025
What this trial tests

NA trial testing AMT-Regenera activa in Knee Osteoarthritis. Withdrawn.

Timeline
1 March 2024
Primary endpoint
1 May 2024
15 May 2024

Quick facts

Lead sponsorHuman Brain Wave S.r.l.
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Start date1 March 2024
Primary completion1 May 2024
Estimated completion15 May 2024

Drugs / interventions tested

Conditions studied

Sponsor

Human Brain Wave S.r.l.

Who can join

Adults 25 to 65, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare in 60 patients suffering for Knee OA to demonstrate that AMT-RegeneraActiva is able to speed up the improvement process of knee osteoarthritis (OA) compared to Sodium Hyaluronate Participants will \[describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items\]. Researchers will compare 2 Groups to see to demonstrate that AMT-RegeneraActiva is able to speed up the improvement process of knee osteoarthritis (OA) compared to Sodium Hyaluronate to pain management and improvement of functionality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06123689.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing